Identification of pathogenesis-related microRNAs in hepatocellular carcinoma by expression profiling

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 817-823

  Katayama, Yuki ^a   Maeda, Moegi ^a   Miyaguchi, Ken ^a   Nemoto, Shota ^a   Yasen, Mahmut ^a   Tanaka, Shinji ^a   Mizushima, Hiroshi ^b   Fukuoka, Yutaka ^a   Arii, Shigeki ^a   Tanaka, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Expression profiling; Hepatocellular carcinoma; Microarray; microRNA

Indexed keywords

MICRORNA; MICRORNA 1228; MICRORNA 1249; MICRORNA 129; MICRORNA 146B 3P; MICRORNA 18B; MICRORNA 2116; MICRORNA 296 5P; MICRORNA 448; MICRORNA 557; MICRORNA 581; MICRORNA 625; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MICROARRAY ANALYSIS; PATHOGENESIS;

EID: 84864666197     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.810     Document Type: Article

References (62)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.
2. Blum H: Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 11: 7391-7400, 2005.
3. Cramp M: HBV + HCV = HCC? Gut 45: 168-169, 1999.
4. Soini Y, Chia SC, Bennett WP, et al: An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 17: 1007-1012, 1996.
5. Boffetta P, Matisane L, Mundt KA and Dell LD: Meta-analysis of studies of occupational exposure to vinyl chloride in relation to cancer mortality. Scand J Work Environ Health 29: 220-229, 2003.
6. Tsukuma H, Hiyama T, Oshima A, et al: A case-control study of hepatocellular carcinoma in Osaka, Japan. Int J Cancer 45: 231-236, 1995.
7. Donato F, Tagger A, Gelatti U, et al: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155: 323-333, 2002.
8. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
9. Yanaihara N, Caplen N, Bowman E, et al: Unique micro RNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
10. Lee EJ, Gusev Y, Jiang J, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007.
11. Murakami Y, Yasuda T, Saigo K, et al: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545, 2006.
12. Budhu A, Jia HL, Forgues M, et al: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47: 897-907, 2008.
13. Varnhort H, Drebber U, Schulze F, et al: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223-1232, 2008.
14. Laderio Y, Couchy G, Balabaud C, et al: MicroRNA profiling in hepatocellular tumor is associated with clinical features and oncogene/tumor suppressors gene mutations. Hepatology 47: 1955-1963, 2008.
15. Li W, Xie L, He X, et al: Diagnostic and prognositic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123: 1616-1622, 2008.
16. Ura S, Honda M, Yamashita T, et al: Differential microRNA expression between hapatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49: 1098-1112, 2009.
17. Toffanin S, Hoshida Y, Lachenmayer A, et al: MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastoenterology 140: 1618-1628, 2011.
18. Yasen M, Mizushima H, Mogushi K, et al: Expression of Aurora B and alterative variant forms in hepatocellular carcinoma and adjacent tissue. Cancer Sci 100: 472-480, 2009.
19. Gramantieri L, Fornari F, Callegari E, et al: MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12: 2189-2204, 2008.
20. Aravalli RN, Steer CJ and Cressman NK: Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063, 2008.
21. Ji J and Wang XW: New kids on the block. Cancer Biol Therapy 8: 1683-1690, 2009.
22. Liang L, Wong CM, Ying Q, et al: MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B. Hepatology 52: 1731-1740, 2010.
23. Osaki M, Takeshita F and Ochiya T: MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 13: 658-670, 2008.
24. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 micro RNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004.
25. Fabbri M, Garzon R, Cimmino A, et al: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810, 2007.
26. Bommer GT, Gerin I, Feng Y, et al: p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298-1307, 2007.
27. Crawford M, Brawner E, Battle K, et al: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373: 607-612, 2008.
28. Hayashita Y, Osada H, Tatematsu Y, et al: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632, 2005.
29. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
30. Garofalo M, Quintavalle C, Di Leva G, et al: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27: 3845-3855, 2008.
31. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
32. Hu Z, Chen J, Tian T, et al: Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 118: 2600-2608, 2008.
33. Yu SL, Chen HY, Chang GC, et al: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57, 2008.
34. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Geogoulias V and Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54: 1696-1704, 2008.
35. Yan LX, Huang XF, Shao Q, et al: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348-2360, 2008.
36. Chan SH, Wu CW, Li AF, Chi CW and Lin WC: miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res 28: 907-911, 2008.
37. Schepeler T, Reinert JT, Ostenfeld MS, et al: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424, 2008.
38. Childs G, Fazzari M, Kung G, et al: Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736-745, 2009.
39. Roldo C, Missiaglia E, Hagan JP, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24: 4677-4684, 2006.
40. Marcucci G, Radmacher MD, Maharry K, et al: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1919-1928, 2008.
41. Calin GA, Ferracin M, Cimmino A, et al: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005.
42. Lu L, Katsaros D, de la Longrais IA, Sochirca O and Yu H: Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 67: 10117-10122, 2007.
43. Guo Y, Chen Z, Zhang L, et al: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68: 26-33, 2008.
44. Chim SS, Shing TK, Hung EC, et al: Detection and characterization of placental microRNAs in material plasma. Clin Chem 54: 482-490, 2008.
45. Gilad S, Meiri E, Yogev Y, et al: Serum microRNAs are promising biomarkers. PLoS One 3: e3148, 2008.
46. Mitchel PS, Parkin RA, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
47. Lawrie CH, Cooper Cd, Ballabio E, Chi J, Tramonti D and Hatton CS: Aberrant expression of microRNA biosynthetic pathways components is a common feature of haematological malignancy. Br. J. Hematol 141: 672-675, 2008.
48. Diaz R, Silva J, Garcia JM, et al: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 47: 794-802, 2008.
49. Schee K, Fodstad O and Flatmark K: MicroRNAs as biomarkers in colorectal cancer. Am J Patho 177: 1592-1599, 2010.
50. Wu WKK, Lee CW, Cho CH, Fan D, Wu K, Yu J and Sung JJY: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29: 5761-5671, 2010.
51. Zavadil J, Ye H, Liu Z, et al: Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS One 5: e12362, 2010.
52. Iorio MV, Piovan C and Croce CM: Interplay between microRNAs and the epigenetic machinery: an intricate network. Boichim Biophys Acta 1799: 694-701, 2010.
53. Valeri N, Vannini I, Fanini F, Calore F, Adair B and Fabbri M: Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 20: 573-580, 2009.
54. Schaefer A, Jung M, Kristiansen G, et al: MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urologic Oncol 28: 4-13, 2010.
55. Garzon R, Marcucci G and Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789, 2010.
56. Calin GA, Liu CG, Sevignani C, et al: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101: 11755-11760, 2004.
57. Betel D, Koppal A, Angius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 11: R90, 2010.
58. Kang JU, Koo SH, Kwon KC, Park JW and Kim JM: Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 82: 1-11, 2008.
59. Yamamoto Y, Chochi Y, Matuyama H, et al: Gain of 5p15.33 is associated with progression of bladder cancer. Oncology 72: 132-138, 2007.
60. Yu K, Ganesan K, Tan LK, et al: A precisely regulated gene expression cassette potentially modulates metastasis and survival in multiple solid cancers. PLoS Genet 4: e1000129, 2008.
61. Bodmer D, Eleveld M, Kater-Baats E, et al: Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). Hum Mol Genet 11: 641-649, 2002.
62. Watanabe Y, Yamasaki F, Kajiwara Y, et al: Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol 100: 449-457, 2010